The DOI matches its Crossref record; 182 of the 185 references it cites were found in a registry or an index.
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Open accessAbstract
The ability of cancer cells to suppress apoptosis is critical for carcinogenesis. The BCL2 family proteins comprise the sentinel network that regulates the mitochondrial or intrinsic apoptotic response. Recent advances in our understanding of apoptotic signaling pathways have enabled methods to identify cancers that are “primed” to undergo apoptosis, and have revealed potential biomarkers that may predict which cancers will undergo apoptosis in response to specific therapies. Complementary efforts have focused on developing novel drugs that directly target antiapoptotic BCL2 family proteins. In this review, we summarize the current knowledge of the role of BCL2 family members in cancer development and response to therapy, focusing on targeted therapeutics, recent progress in the development of apoptotic biomarkers, and therapeutic strategies designed to overcome deficiencies in apoptosis. Significance: Apoptosis, long known to be important for response to conventional cytotoxic chemotherapy, has more recently been shown to be essential for the efficacy of targeted therapies. Approaches that increase the likelihood of a cancer to undergo apoptosis following therapy may help improve targeted treatment strategies. Cancer Discov; 5(5); 475–87. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inhibition of MEK/ERK signaling leads to BIM accumulation and increases apoptotic priming in oncogene-driven cancers treated with various targeted therapies, driving cells into an MCL-1 and/or BCL-XL dependent state15,17.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Suppression of MEK/ERK signaling leads to the accumulation of the pro-apoptotic BCL-2 family protein BIM, which is critical for inducing apoptosis in response to an array of targeted therapies14,15.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [15]
In the citing paper
“Many studies have established a central role of the pro-apoptotic BH3 protein BIM in mediating the apoptotic response to targeted therapies (reviewed in [116]).”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citation
Cited by
Sorted by citations
Items 301–400 of 625
Liang, W., Cai, M., Zhang, M., Cui, S., Zhang, T., Cheng, W., Wu, Y., Ou, W., Jia, Z., & Zhang, S. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/4963346 · Cited by 17
Zwierenga, F., van Veggel, B. A. M. H., van den Berg, A., Groen, H. J. M., Zhang, L., Groves, M. R., Kok, K., Smit, E. F., Hiltermann, T. J. N., Langen, A. J. D., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102628 · Cited by 17
Silver nanoparticles from Ocimum basilicum L. tea: A green route with potent anticancer efficacy
Qamar, S. U. R., Virijević, K. D., Arsenijević, D., Avdović, E., Živanović, M., Filipović, N., Ćirić, A., & Petrović, I. (2024) · Colloids and Interface Science Communications · doi:10.1016/j.colcom.2024.100771 · Cited by 17
Counting on Death – Quantitative aspects of Bcl‐2 family regulation
Hantusch, A., Rehm, M., & Brunner, T. (2018) · FEBS Journal · doi:10.1111/febs.14516 · Cited by 17
Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors
Liu, L., Liu, R., Yang, X., Hou, X., & Fang, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112142 · Cited by 17
Li, H., Zhu, Q.-F., Peng, X., & Peng, B. (2017) · Scientific Reports · doi:10.1038/srep39824 · Cited by 17
Zhou, Y., Liu, H., Xue, R., Tang, W., & Zhang, S. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5253-7 · Cited by 17
Zhao, G., Li, K., Chen, J., & Li, L. (2018) · Translational Neuroscience · doi:10.1515/tnsci-2018-0027 · Cited by 17
LINC01296 promotes neuroblastoma tumorigenesis via the NCL-SOX11 regulatory complex
Wang, J., Wang, Z., Lin, W., Han, Q., Yan, H., Yao, W., Dong, R., Jia, D., Dong, K., & Li, K. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.02.007 · Cited by 16
Ganier, L., Betzi, S., Derviaux, C., Roche, P., Dessaux, C., Muller, C., Hoffer, L., Morelli, X., & Borg, J. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00826 · Cited by 15
Luo, L., Guan, Z., Jin, X., Guan, Z., & Jiang, Y. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00625-6 · Cited by 16
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies
Niscola, P., Gianfelici, V., Catalano, G., Giovannini, M., Mazzone, C., Noguera, N. I., & de Fabritiis, P. (2024) · Current Oncology · doi:10.3390/curroncol31110490 · Cited by 16
BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines
Borst, A., Haferkamp, S., Grimm, J., Rösch, M., Zhu, G., Guo, S., Li, C., Gao, T., Meierjohann, S., Schrama, D., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.005 · Cited by 16
The Influential Role of BCL2 Family Members in Synovial Sarcomagenesis
Barrott, J. J., Zhu, J.-F., Smith-Fry, K., Susko, A. M., Nollner, D., Burrell, L. D., Pozner, A., Capecchi, M. R., Yap, J. T., Cannon‐Albright, L., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0315 · Cited by 15
Discovery of Turn-On Fluorescent Probes for Detecting Bcl-2 Protein
Liu, T., Dong, G., Xu, F., Han, B., Fang, H., Huang, Y. H., Zhou, Y., Du, L., & Li, M. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05853 · Cited by 17
Amuthavalli, K., Kizhakeyil, A., Padmanaban, A. M., Mirza, F. B. S., Vijay, V. R., Lee, P. S., Verma, N. K., Kalaiselvan, P., & Samuel, S. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871521409666200324110031 · Cited by 16
Key genes and drug delivery systems to improve the efficiency of chemotherapy
Torres‐Martínez, Z., Delgado, Y., Ferrer‐Acosta, Y., Suárez-Arroyo, I. J., Joaquín-Ovalle, F. M., Delinois, L. J., & Griebenow, K. H. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.64 · Cited by 16
Li, R., Liu, B., Xu, W., Yu, L., Zhang, C., Cheng, J., Tao, L., Li, Z., & Zhang, Y. (2021) · Environmental Toxicology · doi:10.1002/tox.23432 · Cited by 16
Cold atmospheric plasma as a novel “drug” for cancer therapy
Fu, D., Lin, S., Xu, Q., Cao, F., KHAN, I. A., Xu, S., Li, Z., Chen, Z., Fang, Q., Chen, G., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114118 · Cited by 16
Oroz-Parra, I., Álvarez‐Delgado, C., Cervantes-Luévano, K., Dueñas, S., & Licea-Navarro, A. F. (2019) · Marine Drugs · doi:10.3390/md18010010 · Cited by 15
Kong, Q.-W., Yang, J., Li, D., Ding, Y., Hu, Y., Xue, X.-C., Shi, M., Jiang, B., Zhou, Y.-Y., Zhang, M., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115728 · Cited by 15
Respondek, M., Beberok, A., Rzepka, Z., Rok, J., & Wrześniok, D. M. (2019) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12503 · Cited by 15
Cardamonin as a potential treatment for melanoma induces human melanoma cell apoptosis
Yue, Y., Liu, L., Liu, P., Li, Y., Lu, H., Li, Y., Zhang, G., & Duan, X. (2019) · Oncology Letters · doi:10.3892/ol.2019.11242 · Cited by 15
Apoptotic effects of alisol B 23‑acetate on gastric cancer cells
Kwon, M. S., Kim, J. N., Lee, M., Kim, W. K., Nam, J., & Kim, B. G. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11887 · Cited by 16
Long non-coding RNA AK006774 inhibits cardiac ischemia-reperfusion injury via sponging miR-448
Nie, S., Cui, X., Guo, J., Ma, X., Zhi, H., Li, S., & Li, Y. (2021) · Bioengineered · doi:10.1080/21655979.2021.1954135 · Cited by 15
Gao, X., & Xu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.745011 · Cited by 15
Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
Danilov, A. V., Magagnoli, M., & Matasar, M. J. (2022) · The Oncologist · doi:10.1093/oncolo/oyab004 · Cited by 14
Wang, T., Yang, Z., Zhang, Y., Zhang, X., Wang, L., Zhang, S., & Jia, L. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1436-5 · Cited by 15
Icariin inhibits autophagy and promotes apoptosis in SKVCR cells through mTOR signal pathway
Jiang, S., Chang, H., Deng, S., & Fan, D. (2018) · Cellular and Molecular Biology · doi:10.14715/cmb/2018.64.6.2 · Cited by 15
Settar, A., Khaldoun, H., Tarzaali, D., Djennane, N., Makhlouf, C., Selmani, I., Oularbi, Y., & Amel, K. (2023) · Toxicology · doi:10.1016/j.tox.2023.153464 · Cited by 14
Cellular and molecular mechanisms of oroxylin A in cancer therapy: Recent advances
Wang, P., Mu, X.-N., Huang, S., Hu, K., & Sun, Z.-G. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176452 · Cited by 14
Role of Methylation in the Regulation of Apoptosis Genes APAF1, DAPK1, and BCL2 in Breast Cancer
Loginov, V. I., Валерьевна, П. И., Бурденный, А. М., Pereyaslova, E. A., Александровна, Б. Э., Kazubskaya, T. P., & Кушлинский, Н. Е. (2017) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-017-3716-z · Cited by 14
BLASIO, A. D., Pratelli, G., Drago‐Ferrante, R., Saliba, C., Baldacchino, S., Grech, G., Tesoriere, G., Scerri, C. A., Vento, R., & Fiore, R. D. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28479 · Cited by 14
Amran, N., Wan‐Ibrahim, W. I., Rashid, N. N., Ali, J. M., & Abdul‐Rahman, P. S. (2020) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2020.101149 · Cited by 14
Effects and mechanism of microRNA‑218 against lung cancer
Chen, Y., Yang, J.-L., Xue, Z.-Z., Cai, Q., Hou, C., Li, H., Zhao, L.-X., Yin, Z., Gao, C.-W., Li, C., et al. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11666 · Cited by 14
Transcript-Level Dysregulation of BCL2 Family Genes in Acute Myeloblastic Leukemia
Handschuh, L., Wojciechowski, P., Kaźmierczak, M., & Lewandowski, K. (2021) · Cancers · doi:10.3390/cancers13133175 · Cited by 14
Suppression of PI3K/Akt/mTOR pathway in chrysoeriol-induced apoptosis of rat C6 glioma cells
Wongkularb, S., Limboonreung, T., Tuchinda, P., & Chongthammakun, S. (2021) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-021-00634-x · Cited by 15
Wang, S., Liu, Z., Wang, Y., Shi, B., Jin, Y., Wang, Y., Jiang, X., Song, M., & Yu, W. (2022) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2022.2103479 · Cited by 14
Lai, X., Su, W., Zhao, H., Yang, S., Zeng, T., Wu, W., & Wang, D. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12412 · Cited by 14
Elrazik, N. A. A., El‐Mesery, M., El-Karef, A. A., Eissa, L. A., & Gayar, A. M. E. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2020.1871496 · Cited by 14
Al‐Salam, S., Karthishwaran, K., & Sudhadevi, M. (2021) · Oncotarget · doi:10.18632/oncotarget.27950 · Cited by 13
Clinical Potential of Fruit in Bladder Cancer Prevention and Treatment
Wigner, P., Bijak, M., & Saluk, J. (2022) · Nutrients · doi:10.3390/nu14061132 · Cited by 15
JIANG, X., Yang, X., Yanxia, S. H. I., Yan, L. O. N. G., Wenqing, S. U., Wendong, H. E., Wei, K., & Miao, J. (2023) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(23)60420-0 · Cited by 13
Sun, J., Tian, Z., Wu, J., Li, J., Wang, Q., Huang, S., & Wang, M. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s460093 · Cited by 13
A Synthetic Peptide AWRK6 Alleviates Lipopolysaccharide-Induced Liver Injury
Jin, L., Wang, Q., Zhang, H., Tai, S., Liu, H., & Zhang, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092661 · Cited by 13
Liu, R., Liu, L., Yang, X., & Fang, H. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102938 · Cited by 13
Peroxiredoxin V Reduces β-Lapachone-induced Apoptosis of Colon Cancer Cells
Liu, Y., Kwon, T., Kim, J.-S., Chandimali, N., Jin, Y., Gong, Y.-X., XIE, D.-P., Han, Y., Jin, M., Shen, G., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13516 · Cited by 13
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA
Fairchild, C. K., Floros, K. V., Jacob, S., Coon, C. M., Puchalapalli, M., Hu, B., Harada, H., Dozmorov, M. G., Koblinski, J. E., Smith, S. C., et al. (2021) · Cancers · doi:10.3390/cancers13102310 · Cited by 11
Self-citationVijayan, S., Loganathan, C., Sakayanathan, P., & Palvannan, T. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1959404 · Cited by 13
BCL-2 isoform β promotes angiogenesis by TRiC-mediated upregulation of VEGF-A in lymphoma
Hang, X., Zhao, L., Wu, B., Li, S., Liu, P., Xu, J., Wang, X., Chi, P., Chen, C., Niu, T., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02372-0 · Cited by 13
Discovery and development of substituted tyrosine derivatives as Bcl-2/Mcl-1 inhibitors
Liu, R., Liu, L., Liu, T., Yang, X., Wan, Y., & Fang, H. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.08.030 · Cited by 13
Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells
Massimino, M., Tirrò, E., Stella, S., Pennisi, M. S., Vitale, S. R., Puma, A., Romano, C., Gregorio, S. D., Romeo, M. A., Raimondo, F. D., et al. (2020) · In Vivo · doi:10.21873/invivo.11802 · Cited by 13
Liu, M., Li, F., Feng, S., Guo, J., Yu, J., Zou, S., Gao, X., & Wei, Y. (2024) · Foods · doi:10.3390/foods13223552 · Cited by 12
Liu, Q., Ran, R., Wu, Z., Li, X., Zeng, Q., Xia, R., & Wang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.599070 · Cited by 12
Wen, Y., Zhao, J., He, H., Zhao, Q., & Liu, Z. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c03062 · Cited by 12
Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment
Neely, V. L., Manchikalapudi, A., Nguyen, K., Dalton, K. M., Hu, B., Koblinski, J. E., Faber, A. C., Deb, S., & Harada, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713082 · Cited by 12
Self-citationEssential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins
Antignani, A., Segal, D., Simon, N. C., Kreitman, R. J., Huang, D. C. S., & FitzGerald, D. J. (2017) · Oncogene · doi:10.1038/onc.2017.111 · Cited by 12
Anaya‐Eugenio, G. D., Rebollar-Ramos, D., González, M. D. C., Raja, H. A., Mata, R., & de Blanco, E. J. C. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108798 · Cited by 12
Thymoquinone induces apoptosis via targeting the Bax/BAD and Bcl-2 pathway in breast cancer cells
Yıldırım, İ. H., Azzawri, A. A., & Duran, T. (2019) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/dicletip.620329 · Cited by 12
Yao, X., Niu, F., Kong, L., Cai, F.-Y., Jing, M. X., Fu, M., Liu, J., He, S.-Y., Zhang, L., Liu, X., et al. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2020.1763397 · Cited by 12
Wnętrzak, A., Kubisiak, A., Filiczkowska, A., Gonet-Surówka, A., Chachaj−Brekiesz, A., Targosz‐Korecka, M., & Dynarowicz-Ła̧tka, P. (2021) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2021.183773 · Cited by 12
Xu, H., Jin, J., Chen, L., Li, C., Xu, Q., Shi, J., Zhao, B., Hou, Y., & Wang, H. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/4370381 · Cited by 12
Cowan, J., Shadab, M., Nadkarni, D. H., Kailash, K. C., Velu, S. E., & Yusuf, N. (2019) · Marine Drugs · doi:10.3390/md17080443 · Cited by 12
WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
Yamamoto, G., Tanaka, K., Kamata, R., Saito, H., Yamamori-Morita, T., Nakao, T., Liu, J., Mori, S., Yagishita, S., Hamada, A., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2024.217414 · Cited by 11
Kavousi, M., & Chavoshi, M. S. (2020) · Meta Gene · doi:10.1016/j.mgene.2020.100807 · Cited by 11
Maryamneghari, S. M., Shokri-Asl, V., Abdolmaleki, A., & Jalili, C. (2021) · Andrologia · doi:10.1111/and.14192 · Cited by 11
McAloney, C. A., Makkawi, R., Budhathoki, Y., Cannon, M. V., Franz, E., Gross, A. C., Cam, M., Vetter, T. A., Duhen, R., Davies, A. E., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00867-w · Cited by 12
Dai, L., Zhang, X., Zhou, S., Li, J., Pan, L., Liao, C., Wang, Z., Chen, Y., Shen, G., Li, L., et al. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02543h · Cited by 11
Wang, D., Zhu, J., Lv, J., Zhu, Y., Li, F., Zhang, C., & Yu, X. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132712 · Cited by 12
Xu, Q., Jiang, Z., Pan, Y., Li, S., Cao, Z., Hua, S., Yang, R., He, Q., Wu, H., Wen, H., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157017 · Cited by 12
Rice, S. J., Liu, X., Wang, H., & Belani, C. P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217657 · Cited by 11
Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia
Joshi, K., Zhang, L., Breslin, P., & Zhang, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7342-8_5 · Cited by 14
Monk, J. M., Liddle, D. M., Hutchinson, A. L., Burns, J. L., Wellings, H. R., Cartwright, N. M., Muller, W. J., Power, K. A., Robinson, L. E., & David, W. L. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108763 · Cited by 11
Simon, S. E., Ahmed, U., Saad, S. M., Anwar, A., Khan, K. M., Tan, E. W., & Tan, K. O. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128731 · Cited by 11
Jacob, S., Turner, T. H., Cai, J., Floros, K. V., Yu, A. K., Coon, C. M., Khatri, R., Alzubi, M. A., Jakubik, C. T., Bouck, Y. M., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac232 · Cited by 11
Self-citationFoumani, E. A., Irani, S., Shokoohinia, Y., & Mostafaie, A. (2022) · PubMed Central · doi:10.22074/cellj.2022.8290 · Cited by 17
DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a
Zhou, Y., Perez, R. E., Duan, L., & Maki, C. G. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1433500 · Cited by 11
New biomarkers in non-Hodgkin lymphoma and acute leukemias
Rubio-Jurado, B., Sosa-Quintero, L. S., Carrasco-Martinez, I. L., Norato-Delgado, A., García-Luna, E., Guzmán-Silahua, S., Riebeling‐Navarro, C., & Nava-Zavala, A. H. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.11.002 · Cited by 11
E3 Ubiquitin Ligase ASB17 Promotes Apoptosis by Ubiquitylating and Degrading BCLW and MCL1
Yang, G., Wan, P., Xiang, Q., Huang, S., Huang, S., Wang, J., Wu, K., & Wu, J. (2021) · Biology · doi:10.3390/biology10030234 · Cited by 11
Duplomb, L., Droin, N. M., Bouchot, O., Thauvin‐Robinet, C., Bruel, A., Thévenon, J., Callier, P., Meurice, G., Pata-Merci, N., Loffroy, R., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx349 · Cited by 11
Hua, Z., Zhan, Y., Zhang, S., Dong, Y., Jiang, M., Tan, F., Liu, Z., Thiele, C. J., & Li, Z. (2018) · APOPTOSIS · doi:10.1007/s10495-018-1467-6 · Cited by 11
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58753-y · Cited by 11
“Inhibition of MEK/ERK signaling leads to BIM accumulation and increases apoptotic priming in oncogene-driven cancers treated with various targeted therapies, driving cells into an MCL-1 and/or BCL-XL dependent state 15,17 .”
Self-citationVenetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients
Chatzikalil, E., Roka, K., Diamantopoulos, P. T., Rigatou, E. G., Avgerinou, G., Kattamis, A., & Solomou, E. E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072046 · Cited by 10
miR-137: a potential therapeutic target for lung cancer
Liu, S., Ruan, Y., Chen, X., Bao, H., & Chen, Q. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1427724 · Cited by 10
Yang, Y., Zhang, Y., Yang, C., Fang, F., Wang, Y., Chang, H., Chen, Z., & Chen, P. (2021) · Virology Journal · doi:10.1186/s12985-021-01512-4 · Cited by 10
Manzano-Muñoz, A., Alcon, C., Menéndez, P. R., Ramírez, M. R., Seyfried, F., Debatin, K., Meyer, L. H., Samitier, J., & Montero, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.695225 · Cited by 10
Mukherjee, N., Dart, C. R., Amato, C. M., Honig-Frand, A., Lambert, J. R., Lambert, K. A., Robinson, W. A., Tobin, R. P., McCarter, M. D., Couts, K. L., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.11.035 · Cited by 10
The endoplasmic reticulum participated in drug metabolic toxicity
Huang, Q., Chen, Y., Zhang, Z., Xue, Z., Hua, Z., Luo, X., Yang, L., Lu, C. C., Lü, A., & Liu, Y. (2022) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09689-8 · Cited by 9
Lv, L., Zhou, F., Quan, Y., Fan, Y., Bao, Y., Dou, Y., Qu, H., Dai, X., Zhao, H., Zheng, S., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101989 · Cited by 11
L‑mimosine induces caspase‑9‑mediated apoptosis in human osteosarcoma cells
Xu, Y., & Cai, L. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8403 · Cited by 10
Saadi, W., Kermezli, Y., Dao, L. T. M., Mathieu, È.-L., Santiago‐Algarra, D., Manosalva, I., Torres, M., Belhocine, M., Pradel, L. C., Loriod, B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41247-5 · Cited by 10
FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma
Tétu, P., Delyon, J., André, J., de Moura, C. R., Sabbah, M., Ghanem, G., Battistella, M., Mourah, S., Lebbé, C., & Dumaz, N. (2020) · Cancers · doi:10.3390/cancers12051062 · Cited by 10
The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients
Derebas, J., Panuciak, K., Margas, M., Zawitkowska, J., & Lejman, M. (2022) · Cancers · doi:10.3390/cancers14061569 · Cited by 11
Editorial: Combinatorial Approaches for Cancer Treatment: From Basic to Translational Research
Cerrato, A., Mattheolabakis, G., & Spano, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.842114 · Cited by 10
Chen, X., Yang, Y., Gu, Y., Yi, J., Yao, W., Sha, Z., Wu, H., Zhou, Y., Wu, Z., Bao, F., et al. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2023.11.003 · Cited by 9
Liu, H., Zhou, Y., Wang, Z., Liu, D., Li, Y., Lai, H., Qiu, J., Shan, S., Guo, F., Chen, P., et al. (2025) · MedComm · doi:10.1002/mco2.70129 · Cited by 9
Splice-switching small molecules: A new therapeutic approach to modulate gene expression
Taladriz‐Sender, A., Campbell, E., & Burley, G. A. (2019) · Methods · doi:10.1016/j.ymeth.2019.06.011 · Cited by 9
Zhu, T., Lin, Z., Tang, X., Liu, J., Zhang, Y., & Zhong, X. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124202 · Cited by 9
Serwaa, A., Oyawoye, F. O., Owusu, I. A., Dosoo, D., Manu, A. A., Sobo, A. K., Fosu, K., Olwal, C. O., Quashie, P. K., & Aikins, A. R. (2024) · Scientific Reports · doi:10.1038/s41598-024-75718-1 · Cited by 9
Xia, H. B., Cui, H., Su, L., Zhang, Z. H., Yang, X., Ning, S. Q., & Su, X. (2017) · Genetics and Molecular Research · doi:10.4238/gmr16039278 · Cited by 9
Metadata
- Authors
- Hata, A. N., Engelman, J. A., & Faber, A. C.
- Affiliations
- Harvard University (US)
- Virginia Commonwealth University (US)
- Corresponding author
- Engelman, Jeffrey A.
- Faber, Anthony C.
- Venue
- Cancer Discovery
- Published
- 2015-05-01
- Volume
- 5
- Issue
- 5
- Pages
- 475-487
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4727530
- OpenAlex
- W2067275727
- Cited by
- 619
- References
- 185
- Citations by year
- 2026: 19 · 2025: 48 · 2024: 46 · 2023: 42 · 2022: 69 · 2021: 79 · 2020: 83 · 2019: 79 · 2018: 73 · 2017: 45 · 2016: 29 · 2015: 6
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA127003, R01CA140594, R01CA164273, R01CA137008)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- Bcl-2 family proteins, apoptosis, targeted cancer therapy, mitochondrial apoptosis, cancer therapy response, carcinogenesis, apoptosis resistance
- MeSH terms
- Bcl-2-Like Protein 11, Animals, Antineoplastic Agents, Humans, Membrane Proteins, Neoplasms, Proto-Oncogene Proteins, Signal Transduction, Biomarkers, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Apoptosis Regulatory Proteins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review